1. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
作者: Sydel R Parikh.;Nick J Andrews.;Kazim Beebeejaun.;Helen Campbell.;Sonia Ribeiro.;Charlotte Ward.;Joanne M White.;Ray Borrow.;Mary E Ramsay.;Shamez N Ladhani.
来源: Lancet. 2016年388卷10061期2775-2782页
In September, 2015, the UK became the first country to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a publicly funded national immunisation programme. A reduced two-dose priming schedule was offered to infants at 2 months and 4 months, alongside an opportunistic catch-up for 3 month and 4 month olds. 4CMenB was predicted to protect against 73-88% of MenB strains. We aimed to assess the effectiveness and impact of 4CMenB in vaccine-eligible infants in England.
2. Caustic ingestion.
作者: Mircea Chirica.;Luigi Bonavina.;Michael D Kelly.;Emile Sarfati.;Pierre Cattan.
来源: Lancet. 2017年389卷10083期2041-2052页
Corrosive ingestion is a rare but potentially devastating event and, despite the availability of effective preventive public health strategies, injuries continue to occur. Most clinicians have limited personal experience and rely on guidelines; however, uncertainty persists about best clinical practice. Ingestions range from mild cases with no injury to severe cases with full thickness necrosis of the oesophagus and stomach. CT scan is superior to traditional endoscopy for stratification of patients to emergency resection or observation. Oesophageal stricture is a common consequence of ingestion and newer stents show some promise; however, the place of endoscopic stenting for corrosive strictures is yet to be defined. We summarise the evidence to provide a plan for managing these potentially life-threatening injuries and discuss the areas where further research is required to improve outcomes.
3. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
作者: Brian G M Durie.;Antje Hoering.;Muneer H Abidi.;S Vincent Rajkumar.;Joshua Epstein.;Stephen P Kahanic.;Mohan Thakuri.;Frederic Reu.;Christopher M Reynolds.;Rachael Sexton.;Robert Z Orlowski.;Bart Barlogie.;Angela Dispenzieri.
来源: Lancet. 2017年389卷10068期519-527页
Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed to study whether the addition of bortezomib to lenalidomide and dexamethasone would improve progression-free survival and provide better response rates in patients with previously untreated multiple myeloma who were not planned for immediate autologous stem-cell transplant.
4. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
作者: Ana Maria Henao-Restrepo.;Anton Camacho.;Ira M Longini.;Conall H Watson.;W John Edmunds.;Matthias Egger.;Miles W Carroll.;Natalie E Dean.;Ibrahima Diatta.;Moussa Doumbia.;Bertrand Draguez.;Sophie Duraffour.;Godwin Enwere.;Rebecca Grais.;Stephan Gunther.;Pierre-Stéphane Gsell.;Stefanie Hossmann.;Sara Viksmoen Watle.;Mandy Kader Kondé.;Sakoba Kéïta.;Souleymane Kone.;Eewa Kuisma.;Myron M Levine.;Sema Mandal.;Thomas Mauget.;Gunnstein Norheim.;Ximena Riveros.;Aboubacar Soumah.;Sven Trelle.;Andrea S Vicari.;John-Arne Røttingen.;Marie-Paule Kieny.
来源: Lancet. 2017年389卷10068期505-518页
rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa.
5. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Feng-Cai Zhu.;Alie H Wurie.;Li-Hua Hou.;Qi Liang.;Yu-Hua Li.;James B W Russell.;Shi-Po Wu.;Jing-Xin Li.;Yue-Mei Hu.;Qiang Guo.;Wen-Bo Xu.;Abdul R Wurie.;Wen-Juan Wang.;Zhe Zhang.;Wen-Jiao Yin.;Manal Ghazzawi.;Xu Zhang.;Lei Duan.;Jun-Zhi Wang.;Wei Chen.
来源: Lancet. 2017年389卷10069期621-628页
A recombinant adenovirus type-5 vector-based vaccine expressing the glycoprotein of Ebola Zaire Makona variant showed good safety and immunogenicity in a phase 1 trial of healthy Chinese adults. We aimed to assess the safety and immunogenicity of this vaccine in healthy adults in Sierra Leone and to determine the optimal dose.
6. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Richard B Warren.;Ulrich Mrowietz.;Ralph von Kiedrowski.;Johannes Niesmann.;Dagmar Wilsmann-Theis.;Kamran Ghoreschi.;Ina Zschocke.;Thomas M Falk.;Norbert Blödorn-Schlicht.;Kristian Reich.
来源: Lancet. 2017年389卷10068期528-537页
Methotrexate is one of the most commonly used systemic drugs for the treatment of moderate to severe psoriasis; however, high-quality evidence for its use is sparse and limited to use of oral dosing. We aimed to assess the effect of an intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis.
7. Pelvic floor muscle training for secondary prevention of pelvic organ prolapse (PREVPROL): a multicentre randomised controlled trial.
作者: Suzanne Hagen.;Cathryn Glazener.;Doreen McClurg.;Christine Macarthur.;Andrew Elders.;Peter Herbison.;Don Wilson.;Philip Toozs-Hobson.;Christine Hemming.;Jean Hay-Smith.;Marissa Collins.;Sylvia Dickson.;Janet Logan.
来源: Lancet. 2017年389卷10067期393-402页
Pelvic floor muscle training can reduce prolapse severity and symptoms in women seeking treatment. We aimed to assess whether this intervention could also be effective in secondary prevention of prolapse and the need for future treatment.
8. Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study.
作者: Joanne R Morling.;David A McAllister.;Wael Agur.;Colin M Fischbacher.;Cathryn M A Glazener.;Karen Guerrero.;Leanne Hopkins.;Rachael Wood.
来源: Lancet. 2017年389卷10069期629-640页
Concerns have been raised about the safety of surgery for stress urinary incontinence and pelvic organ prolapse using transvaginal mesh. We assessed adverse outcomes after first, single mesh procedures and comparable non-mesh procedures.
9. Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT).
作者: Cathryn Ma Glazener.;Suzanne Breeman.;Andrew Elders.;Christine Hemming.;Kevin G Cooper.;Robert M Freeman.;Anthony Rb Smith.;Fiona Reid.;Suzanne Hagen.;Isobel Montgomery.;Mary Kilonzo.;Dwayne Boyers.;Alison McDonald.;Gladys McPherson.;Graeme MacLennan.;John Norrie.; .
来源: Lancet. 2017年389卷10067期381-392页
The use of transvaginal mesh and biological graft material in prolapse surgery is controversial and has led to a number of enquiries into their safety and efficacy. Existing trials of these augmentations are individually too small to be conclusive. We aimed to compare the outcomes of prolapse repair involving either synthetic mesh inlays or biological grafts against standard repair in women.
10. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
作者: Firas H El-Khatib.;Courtney Balliro.;Mallory A Hillard.;Kendra L Magyar.;Laya Ekhlaspour.;Manasi Sinha.;Debbie Mondesir.;Aryan Esmaeili.;Celia Hartigan.;Michael J Thompson.;Samir Malkani.;J Paul Lock.;David M Harlan.;Paula Clinton.;Eliana Frank.;Darrell M Wilson.;Daniel DeSalvo.;Lisa Norlander.;Trang Ly.;Bruce A Buckingham.;Jamie Diner.;Milana Dezube.;Laura A Young.;April Goley.;M Sue Kirkman.;John B Buse.;Hui Zheng.;Rajendranath R Selagamsetty.;Edward R Damiano.;Steven J Russell.
来源: Lancet. 2017年389卷10067期369-380页
The safety and effectiveness of a continuous, day-and-night automated glycaemic control system using insulin and glucagon has not been shown in a free-living, home-use setting. We aimed to assess whether bihormonal bionic pancreas initialised only with body mass can safely reduce mean glycaemia and hypoglycaemia in adults with type 1 diabetes who were living at home and participating in their normal daily routines without restrictions on diet or physical activity.
11. Syphilis.
Syphilis is a chronic bacterial infection caused by Treponema pallidum that is endemic in low-income countries and and occurs at lower rates in middle-income and high-income countries. The disease is of both individual and public health importance and, in addition to its direct morbidity, increases risk of HIV infection and can cause lifelong morbidity in children born to infected mothers. Without treatment the disease can progress over years through a series of clinical stages and lead to irreversible neurological or cardiovascular complications. Although syphilis is an ancient disease and the principles of recommended management have been established for decades, diagnosis and management are often challenging because of its varied manifestations and difficulty in interpretation of serological tests used to confirm diagnosis and evaluate response to therapy. In North America and western Europe, incidence of syphilis has increased dramatically in the past decade among men who have sex with men, particularly those with coexistent HIV infection. Only one drug, penicillin, is recommended for syphilis treatment and response to therapy is assessed based on changes over months in serological test titres. Treatment for patients who cannot receive penicillin and management of patients who do not serologically respond to treatment are common clinical problems.
12. Counselling for Alcohol Problems (CAP), a lay counsellor-delivered brief psychological treatment for harmful drinking in men, in primary care in India: a randomised controlled trial.
作者: Abhijit Nadkarni.;Benedict Weobong.;Helen A Weiss.;Jim McCambridge.;Bhargav Bhat.;Basavaraj Katti.;Pratima Murthy.;Michael King.;David McDaid.;A-La Park.;G Terence Wilson.;Betty Kirkwood.;Christopher G Fairburn.;Richard Velleman.;Vikram Patel.
来源: Lancet. 2017年389卷10065期186-195页
Although structured psychological treatments are recommended as first-line interventions for harmful drinking, only a small fraction of people globally receive these treatments because of poor access in routine primary care. We assessed the effectiveness and cost-effectiveness of Counselling for Alcohol Problems (CAP), a brief psychological treatment delivered by lay counsellors to patients with harmful drinking attending routine primary health-care settings.
13. The Healthy Activity Program (HAP), a lay counsellor-delivered brief psychological treatment for severe depression, in primary care in India: a randomised controlled trial.
作者: Vikram Patel.;Benedict Weobong.;Helen A Weiss.;Arpita Anand.;Bhargav Bhat.;Basavraj Katti.;Sona Dimidjian.;Ricardo Araya.;Steve D Hollon.;Michael King.;Lakshmi Vijayakumar.;A-La Park.;David McDaid.;Terry Wilson.;Richard Velleman.;Betty R Kirkwood.;Christopher G Fairburn.
来源: Lancet. 2017年389卷10065期176-185页
Although structured psychological treatments are recommended as first-line interventions for depression, only a small fraction of people globally receive these treatments because of poor access in routine primary care. We assessed the effectiveness and cost-effectiveness of a brief psychological treatment (Healthy Activity Program [HAP]) for delivery by lay counsellors to patients with moderately severe to severe depression in primary health-care settings.
14. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
作者: Séverine Vermeire.;Stefan Schreiber.;Robert Petryka.;Tanja Kuehbacher.;Xavier Hebuterne.;Xavier Roblin.;Maria Klopocka.;Adrian Goldis.;Maria Wisniewska-Jarosinska.;Andrey Baranovsky.;Robert Sike.;Kremena Stoyanova.;Chantal Tasset.;Annegret Van der Aa.;Pille Harrison.
来源: Lancet. 2017年389卷10066期266-275页
Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and safety of filgotinib for the treatment of moderate-to-severe Crohn's disease.
15. Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort study.
作者: Paul D Griffiths.;Michael Bradburn.;Michael J Campbell.;Cindy L Cooper.;Ruth Graham.;Deborah Jarvis.;Mark D Kilby.;Gerald Mason.;Cara Mooney.;Stephen C Robson.;Allan Wailoo.; .
来源: Lancet. 2017年389卷10068期538-546页
In-utero MRI (iuMRI) has shown promise as an adjunct to ultrasound but the comparative diagnostic performance has been poorly defined. We aimed to assess whether the diagnostic accuracy and confidence of the prenatal diagnosis of fetal brain abnormalities is improved with iuMRI and assess the clinical impact and patient acceptability of iuMRI.
16. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
作者: Achim Rittmeyer.;Fabrice Barlesi.;Daniel Waterkamp.;Keunchil Park.;Fortunato Ciardiello.;Joachim von Pawel.;Shirish M Gadgeel.;Toyoaki Hida.;Dariusz M Kowalski.;Manuel Cobo Dols.;Diego L Cortinovis.;Joseph Leach.;Jonathan Polikoff.;Carlos Barrios.;Fairooz Kabbinavar.;Osvaldo Arén Frontera.;Filippo De Marinis.;Hande Turna.;Jong-Seok Lee.;Marcus Ballinger.;Marcin Kowanetz.;Pei He.;Daniel S Chen.;Alan Sandler.;David R Gandara.; .
来源: Lancet. 2017年389卷10066期255-265页
Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.
17. Differential effect of mass deworming and targeted deworming for soil-transmitted helminth control in children: a systematic review and meta-analysis.
作者: Naomi E Clarke.;Archie C A Clements.;Suhail A Doi.;Dongxu Wang.;Suzy J Campbell.;Darren Gray.;Susana V Nery.
来源: Lancet. 2017年389卷10066期287-297页
Soil-transmitted helminth infections are a major global health issue, causing substantial morbidity in the world's poorest populations. Regular delivery of anthelmintic drugs is the mainstay for global soil-transmitted helminth control. Deworming campaigns are often targeted to school-aged children, who are at high risk of soil-transmitted-helminth-associated morbidity. However, findings from modelling studies suggest that deworming campaigns should be expanded community-wide for effective control of soil-transmitted helminth transmission. We aimed to do a systematic review and meta-analysis to compare the effect of mass (community-wide) and targeted (children only) anthelmintic delivery strategies on soil-transmitted helminth prevalence in school-aged children.
18. Dynamic contrast-enhanced MRI to predict response to vinorelbine-cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial.
作者: Rui Zhang.;Zhi-Yu Wang.;Yue-Hua Li.;Yao-Hong Lu.;Shuai Wang.;Wen-Xi Yu.;Hui Zhao.
来源: Lancet. 2016年388 Suppl 1卷S95页
Metastatic bone disease is a frequent complication of advanced non-small-cell lung cancer and causes skeletal-related events which result in a poor prognosis. A standard method to assess the therapeutic response of bone metastases does not currently exist. We used dynamic contrast-enhanced MRI to obtain quantitative measures to assess the suitability of this technique to gauge therapeutic response to vinorelbine-cisplatin plus rh-endostatinfor previously untreated non-small cell lung cancer with bone metastases.
19. Massive misuse of antibiotics by university students in China: a cross-sectional survey.
Antimicrobial resistance is one of the greatest threats to global population health this century, and is a major contributor to rising healthcare costs worldwide. The primary cause of this resistance is antibiotic misuse, especially routine inappropriate use of antibiotics for self-limiting illnesses. In China, over prescribing of antibiotics is pervasive leading to very high and increasing rates of antimicrobial resistance in both hospital-acquired and community-acquired infections. The aim of this study was to explore the knowledge and behaviours of university students in relation to antibiotic use in six Chinese provinces.
20. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
作者: Arjun V Balar.;Matthew D Galsky.;Jonathan E Rosenberg.;Thomas Powles.;Daniel P Petrylak.;Joaquim Bellmunt.;Yohann Loriot.;Andrea Necchi.;Jean Hoffman-Censits.;Jose Luis Perez-Gracia.;Nancy A Dawson.;Michiel S van der Heijden.;Robert Dreicer.;Sandy Srinivas.;Margitta M Retz.;Richard W Joseph.;Alexandra Drakaki.;Ulka N Vaishampayan.;Srikala S Sridhar.;David I Quinn.;Ignacio Durán.;David R Shaffer.;Bernhard J Eigl.;Petros D Grivas.;Evan Y Yu.;Shi Li.;Edward E Kadel.;Zachary Boyd.;Richard Bourgon.;Priti S Hegde.;Sanjeev Mariathasan.;AnnChristine Thåström.;Oyewale O Abidoye.;Gregg D Fine.;Dean F Bajorin.; .
来源: Lancet. 2017年389卷10064期67-76页
First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients.
|